What's Happening?
REGENXBIO is set to resubmit its application for the gene therapy RGX-121, targeting Hunter syndrome, after the FDA reversed its previous decision. Initially, the FDA had rejected the application, citing concerns over study eligibility criteria and the use
of external controls. However, following a collaborative discussion, the FDA has now deemed the existing clinical data sufficient for an accelerated approval pathway. This decision aligns with a broader trend of the FDA adopting a more flexible approach towards rare disease therapies under acting commissioner Kyle Diamantas.
Why It's Important?
The FDA's decision to reconsider RGX-121's application is a significant development for REGENXBIO and the broader biotech industry. It reflects a shift towards more accommodating regulatory practices for rare disease treatments, potentially accelerating the availability of innovative therapies for patients with unmet medical needs. This move could encourage other biotech companies to pursue similar pathways, fostering innovation and investment in the rare disease sector. For REGENXBIO, successful approval of RGX-121 could enhance its market position and provide a much-needed treatment option for patients with Hunter syndrome.
What's Next?
REGENXBIO plans to hold a Type A meeting with the FDA in July to review existing data and discuss the resubmission of its biologics license application. The company aims to submit the application in the third quarter, with the FDA expected to review it on an expedited basis. This process will be closely monitored by investors and stakeholders, as it could set a precedent for future regulatory interactions in the rare disease space. The outcome may also influence the strategies of other companies developing gene therapies.
